Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials

Fig. 2

Overall PBSC collection results. a The percentages of patients reaching collection goal of > 6 × 106 CD34 + cells /kg bw according to collection days are displayed. b The proportion of patients receiving pre-emptive or rescue mobilization with plerixafor is shown. c The overall CD34+ cell collection result after all LP sessions are shown. d Percentage of patients reaching the collection goal of > 6 × 106 CD34 + cells /kg bw after all LP sessions are depicted. Abbreviations: bw, body weight; d, days; Elo, elotuzumab; Isa, isatuximab; LP, leukapheresis; PB, peripheral blood; PBSC, peripheral blood stem cells, RVd, lenalidomide, bortezomib, dexamethasone

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us